You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR MEROPENEM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Meropenem

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00050401 ↗ Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support Completed AstraZeneca Phase 3 2002-07-01 The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support. The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion (release of the drug into the bloodstream), levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem) or other antibiotics.
NCT00050401 ↗ Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support Completed Pfizer Phase 3 2002-07-01 The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support. The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion (release of the drug into the bloodstream), levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem) or other antibiotics.
NCT00061438 ↗ A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died Completed AstraZeneca Phase 4 2003-02-01 This is a research study in patients having a condition known as necrotizing pancreatitis. This is inflammation of the pancreas (an intestinal organ which assists with digestion) that has resulted in the damage and death of some pancreatic tissue. This damaged pancreatic tissue may develop a bacterial infection, which can cause further -sometimes very serious- health problems. It may be possible to prevent or delay infection by giving 'prophylactic' antibiotics (that is - to provide protection before any infection starts). However, it is not certain that this antibiotic therapy will be successful. This study is being carried out to see whether the antibiotic 'Meropenem' (which is also known as MERREM I.V.) provides protection from developing a pancreatic infection. This will be done by comparing the progress of patients who receive meropenem with those who receive a non-active placebo solution (a solution that does not contain any active medication). Meropenem or placebo would be given in addition to the standard treatment received for pancreatitis. It is not known if meropenem will help prevent infections associated with necrotizing pancreatitis. Approximately 240 patients will take part in this study. Study participation will be carried out for up to 6 weeks, and patients will receive the study treatment up to a maximum of 21 days.
NCT00061438 ↗ A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died Completed Pfizer Phase 4 2003-02-01 This is a research study in patients having a condition known as necrotizing pancreatitis. This is inflammation of the pancreas (an intestinal organ which assists with digestion) that has resulted in the damage and death of some pancreatic tissue. This damaged pancreatic tissue may develop a bacterial infection, which can cause further -sometimes very serious- health problems. It may be possible to prevent or delay infection by giving 'prophylactic' antibiotics (that is - to provide protection before any infection starts). However, it is not certain that this antibiotic therapy will be successful. This study is being carried out to see whether the antibiotic 'Meropenem' (which is also known as MERREM I.V.) provides protection from developing a pancreatic infection. This will be done by comparing the progress of patients who receive meropenem with those who receive a non-active placebo solution (a solution that does not contain any active medication). Meropenem or placebo would be given in addition to the standard treatment received for pancreatitis. It is not known if meropenem will help prevent infections associated with necrotizing pancreatitis. Approximately 240 patients will take part in this study. Study participation will be carried out for up to 6 weeks, and patients will receive the study treatment up to a maximum of 21 days.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Meropenem

Condition Name

Condition Name for Meropenem
Intervention Trials
Sepsis 11
Acute Pyelonephritis 8
Septic Shock 8
Complicated Intra-abdominal Infection 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Meropenem
Intervention Trials
Infections 48
Infection 40
Communicable Diseases 39
Sepsis 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Meropenem

Trials by Country

Trials by Country for Meropenem
Location Trials
United States 215
China 54
Spain 47
Italy 29
India 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Meropenem
Location Trials
California 19
Ohio 18
Florida 16
New York 15
Texas 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Meropenem

Clinical Trial Phase

Clinical Trial Phase for Meropenem
Clinical Trial Phase Trials
Phase 4 36
Phase 3 40
Phase 2/Phase 3 5
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Meropenem
Clinical Trial Phase Trials
Completed 66
Not yet recruiting 22
Recruiting 19
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Meropenem

Sponsor Name

Sponsor Name for Meropenem
Sponsor Trials
Pfizer 12
AstraZeneca 10
Merck Sharp & Dohme Corp. 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Meropenem
Sponsor Trials
Other 161
Industry 79
U.S. Fed 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Meropenem: Clinical Trials, Market Analysis, and Projections

Introduction

Meropenem, a broad-spectrum β-lactam antibiotic, is widely used in the treatment of severe infections, including sepsis and nosocomial pneumonia. This article provides an update on recent clinical trials, market analysis, and future projections for meropenem.

Clinical Trials Update

Continuous vs Intermittent Administration

A significant clinical trial, the MERCY study, investigated the efficacy of continuous versus intermittent administration of meropenem in critically ill patients with sepsis or septic shock. This double-blind, randomized clinical trial, involving 607 patients across 31 intensive care units in four countries, found that continuous administration of meropenem did not improve clinically relevant outcomes compared to intermittent administration. The study reported no significant difference in the composite outcome of all-cause mortality and the emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28[1].

Therapeutic Drug Monitoring (TDM)

Another study highlighted the importance of TDM in optimizing meropenem dosing. This retrospective study used software-guided empiric dosing and TDM to adjust meropenem doses, ensuring therapeutic concentrations without exceeding toxic levels. The study demonstrated that TDM-guided dose adjustments, interpreted by trained clinical pharmacists, can achieve higher target achievements and avoid potentially harmful concentrations[3].

Market Analysis

Global Market Trends

The global meropenem injection market is expected to grow, driven by increasing demand for effective antibacterial drugs. The market size in 2023 was significant, with a projected compound annual growth rate (CAGR) from 2024 to 2031. The market is segmented by type, application, and region, with North America, Europe, Asia Pacific, Middle East & Africa, and Latin America being the major regions[5].

Impact of COVID-19

The COVID-19 pandemic had a notable impact on the meropenem market, particularly in China. The sales revenue of meropenem in China decreased by 12.2% in 2020 due to the pandemic's effect on hospital operations. However, as the epidemic situation improved, the market is expected to recover and grow from 2021 to 2025[2].

Competitive Landscape

The meropenem market is competitive, with several key manufacturers. In China, companies like Sumitomo Dainippon Pharma Co Ltd, Shenzhen Haibin Pharmaceutical Co., Ltd., and CSPC Ouyi Pharmaceutical Group Co., Ltd. are major players. These companies have significant market shares in terms of sales value and volume[2].

Market Projections

Revenue Growth

The global meropenem injection market is forecasted to experience revenue growth from 2024 to 2031. This growth is driven by increasing demand for effective antibiotics, especially in regions with high incidence rates of severe infections. The market report provides detailed insights into regional and country-level trends, helping to understand the future prospects of the meropenem injection market[5].

Regional Analysis

The market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Each region has its own growth rate and market dynamics, influenced by factors such as healthcare infrastructure, regulatory policies, and disease prevalence. The Asia Pacific region, particularly China, is expected to show significant growth due to the recovery from the COVID-19 pandemic and the increasing demand for antibacterial drugs[5].

Application and Type Analysis

Meropenem is used in various applications, including the treatment of nosocomial pneumonia, sepsis, and other severe infections. The market analysis also segments meropenem by type, such as injections, and other dosage forms. Understanding these segments helps in identifying the most lucrative areas for future growth and investment[5].

Efficacy and Tolerability

Clinical Efficacy

Meropenem has shown efficacy in clinical trials as an initial empirical therapy for the treatment of nosocomial pneumonia and other severe infections. Its broad-spectrum activity makes it a valuable option in intensive care settings[4].

Safety Profile

Meropenem is generally well-tolerated, with a safety profile that includes minimal adverse events such as seizures or allergic reactions. The MERCY study reported no such adverse events related to the study drug[1].

Key Takeaways

  • Clinical Trials: Continuous administration of meropenem does not improve clinically relevant outcomes compared to intermittent administration in critically ill patients.
  • Market Trends: The global meropenem market is expected to grow, driven by increasing demand for effective antibacterial drugs.
  • COVID-19 Impact: The pandemic affected the meropenem market in China, but the market is expected to recover and grow.
  • Regional Growth: Asia Pacific, particularly China, is expected to show significant growth.
  • Efficacy and Safety: Meropenem is effective and well-tolerated, making it a valuable option in intensive care settings.

FAQs

What is the current consensus on the administration of meropenem in critically ill patients?

The MERCY study indicates that continuous administration of meropenem does not improve clinically relevant outcomes compared to intermittent administration in critically ill patients with sepsis or septic shock[1].

How has the COVID-19 pandemic impacted the meropenem market in China?

The COVID-19 pandemic led to a 12.2% decrease in meropenem sales revenue in China in 2020. However, the market is expected to recover and grow as the epidemic situation improves[2].

What are the key applications of meropenem?

Meropenem is primarily used in the treatment of nosocomial pneumonia, sepsis, and other severe infections[4].

What is the role of Therapeutic Drug Monitoring (TDM) in meropenem dosing?

TDM is crucial in optimizing meropenem doses to ensure therapeutic concentrations without exceeding toxic levels, especially in patients with varying renal function[3].

What are the projections for the global meropenem injection market?

The global meropenem injection market is forecasted to experience revenue growth from 2024 to 2031, driven by increasing demand for effective antibacterial drugs[5].

Sources

  1. JAMA Network: Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis or Septic Shock.
  2. Research and Markets: Investigation Report on China's Meropenem Market 2021-2025.
  3. MDPI: Software- and TDM-Guided Dosing of Meropenem Promises High Target Achievements.
  4. Oxford Academic: Update on the Efficacy and Tolerability of Meropenem in the Treatment of Nosocomial Pneumonia.
  5. Cognitive Market Research: Meropenem Injection Market Report 2024 (Global Edition).

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.